Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

18.1K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
18.1K
Drug Delivery: Parenteral Route01:29

Drug Delivery: Parenteral Route

1.3K
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
1.3K
Experimental RNAi02:15

Experimental RNAi

7.1K
RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
7.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dysregulation of Central-Medial Amygdala Histone Modifiers in Preclinical Models of Ethanol Exposure.

Addiction biology·2025
Same author

Drug Sensitivity Testing in Osteosarcoma: A Case Report.

Current oncology (Toronto, Ont.)·2025
Same author

Natural antisense transcripts as versatile regulators of gene expression.

Nature reviews. Genetics·2024
Same author

Contextualizing the Role of Osteopontin in the Inflammatory Responses of Alzheimer's Disease.

Biomedicines·2023
Same author

Low-Dose Chidamide Treatment Displays Sex-Specific Differences in the 3xTg-AD Mouse.

Biomolecules·2023
Same author

Amplifying gene expression with RNA-targeted therapeutics.

Nature reviews. Drug discovery·2023

Related Experiment Video

Updated: Dec 15, 2025

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
14:55

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Published on: May 12, 2013

61.5K

Direct Administration and Gene Modulation Using Antisense Oligonucleotides Within the CNS.

Claes Wahlestedt1, Olga Khorkova2

  • 1Center for Therapeutic Innovation, University of Miami Miller School of Medicine, Miami, FL, USA. cwahlestedt@med.miami.edu.

Cellular and Molecular Neurobiology
|July 14, 2020
PubMed
Summary

Dr. Pasternak pioneered antisense oligonucleotide (ASO) research, overcoming the blood-brain barrier challenge for central nervous system gene knockdown. Early ASO delivery methods paved the way for today's ASO-based therapeutics.

Keywords:
Antisense oligonucleotidesCNSG.W. PasternakIntracerebroventricular injectionIntrathecal injection

More Related Videos

Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System
07:47

Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System

Published on: October 29, 2019

19.4K
Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation
08:37

Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation

Published on: December 22, 2020

4.1K

Related Experiment Videos

Last Updated: Dec 15, 2025

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System
14:55

Direct Intraventricular Delivery of Drugs to the Rodent Central Nervous System

Published on: May 12, 2013

61.5K
Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System
07:47

Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System

Published on: October 29, 2019

19.4K
Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation
08:37

Focused Ultrasound Induced Blood-Brain Barrier Opening for Targeting Brain Structures and Evaluating Chemogenetic Neuromodulation

Published on: December 22, 2020

4.1K

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Pharmacology

Background:

  • Dr. G. W. Pasternak's early work significantly contributed to opioid receptor studies.
  • He was a pioneer in the antisense oligonucleotide (ASO) field during its nascent stages.
  • Initial challenges in ASO research included the inability of ASOs to effectively cross the blood-brain barrier for in vivo studies in the central nervous system (CNS).

Purpose of the Study:

  • To highlight Dr. Pasternak's foundational contributions to the field of antisense oligonucleotides (ASOs).
  • To detail the early development of ASO delivery methods overcoming the blood-brain barrier.
  • To underscore the impact of these early studies on current ASO-based therapeutic advancements.

Main Methods:

  • Pioneering intracerebroventricular (ICV) and intrathecal (IT) injection techniques for oligonucleotide administration in the CNS.
  • Collaborative research efforts between Cornell University Medical College and the Pasternak lab.
  • In vivo studies focusing on ASO-mediated gene knockdown in the CNS.

Main Results:

  • Successful development of methods for delivering oligonucleotides across the blood-brain barrier starting in the early 1990s.
  • Demonstration of effective ASO-mediated gene knockdown in the CNS through ICV and IT administration.
  • Established the feasibility and therapeutic potential of ASO technology for CNS applications.

Conclusions:

  • Early advancements in ASO delivery, particularly through ICV and IT routes, were critical.
  • These foundational studies, in collaboration with Dr. Pasternak's lab, were instrumental in overcoming major hurdles in ASO research.
  • The pioneering work directly contributed to the realization of the therapeutic potential of ASO-based drugs currently in use.